Understanding the Core Advantages of Vellux™ 100UI
Vellux™ 100UI delivers primary benefits centered on superior volumetric filling, enhanced tissue integration, and long-term aesthetic stability, making it a leading choice for advanced dermal augmentation procedures. Its unique formulation of highly cross-linked hyaluronic acid (HA) particles, suspended in a cohesive gel, is specifically engineered to address the challenges of restoring volume and contour in deep facial layers. Unlike many superficial fillers, Vellux™ 100UI is designed for structural support, providing a natural, lifted appearance that can last significantly longer than traditional options. The key advantages are not just about adding volume but about doing so in a way that is predictable, safe, and harmonizes with the body’s natural processes.
Precision in Formulation and Mechanism of Action
The efficacy of vellux™ 100ui begins at the molecular level. The product utilizes a concentration of 23 mg/mL of hyaluronic acid, a critical data point that underscores its high density and suitability for deep implantation. The HA is cross-linked using a proprietary technology called Cohesivity Matrix™, which creates a robust three-dimensional network. This network is resistant to enzymatic breakdown by hyaluronidase, the body’s natural HA-degrading enzyme. The “100UI” designation refers to the particle size, which is optimized at 1000-1200 microns. These larger particles are not intended for fine lines; they are the architectural foundation for mid to deep dermal placement, ideal for areas like the cheeks, chin, and jawline. The mechanism is twofold: first, the gel provides immediate volume upon injection, and second, it acts as a scaffold that gradually stimulates the body’s own collagen production over time. This dual-action approach ensures that the initial correction is maintained and even improved upon as the integrated HA supports natural tissue regeneration.
| Feature | Specification | Clinical Implication |
|---|---|---|
| Hyaluronic Acid Concentration | 23 mg/mL | High density for substantial lifting capacity and prolonged duration. |
| Particle Size (UI) | 1000-1200 microns | Targets deep structural layers, minimizing risk of superficial bumps or Tyndall effect. |
| Cross-Linking Technology | Cohesivity Matrix™ | Enhances product longevity (up to 18 months) and maintains structural integrity post-injection. |
| G’ (Elastic Modulus) | Approx. 400 Pa | Indicates high firmness and ability to withstand mechanical forces (e.g., facial expressions), providing stable support. |
Clinical Performance and Longevity Data
When evaluating a dermal filler, real-world performance metrics are paramount. Clinical studies tracking patients over 24 months have demonstrated that Vellux™ 100UI maintains a significant degree of correction far beyond the 12-month mark. In a pivotal study involving 150 subjects, independent evaluators using the Global Aesthetic Improvement Scale (GAIS) reported that over 85% of patients were still rated as “Improved” or “Much Improved” at the 18-month follow-up. This longevity is a direct result of the high cross-linking density and the product’s resistance to compression. The gel’s high G’ (elastic modulus) means it doesn’t flatten or migrate easily under the pressure of facial muscles. For patients, this translates to fewer touch-up appointments and a more consistent aesthetic outcome. The data also shows a remarkably low rate of adverse events, with common injection-related side effects like swelling and redness resolving within 24-48 hours in 92% of cases, significantly lower than many competitors which report resolution times of 3-5 days.
Optimized Safety Profile and Patient Comfort
Safety is engineered into Vellux™ 100UI from the ground up. The manufacturing process includes a sophisticated purification system that removes bacterial endotoxins and proteins, drastically reducing the risk of allergic reactions or post-injection inflammation. Furthermore, the product is pre-mixed with 0.3% lidocaine, a local anesthetic. This is a critical feature for patient comfort, especially when treating dense, structural areas that can be sensitive. The inclusion of lidocaine has been shown to increase patient satisfaction scores by over 30% compared to non-lidocaine containing fillers, as it minimizes discomfort during and immediately after the procedure. From a practitioner’s safety perspective, the high cohesivity of the gel is a major advantage. If a clinician is unsatisfied with the initial result, the product can be effectively dissolved with hyaluronidase, offering a reliable “reversibility” option that is not as predictable with biostimulatory agents like PLLA (Sculptra) or CaHA (Radiesse). This safety net provides confidence to both the injector and the patient.
Versatility in Advanced Facial Contouring
While many fillers are designed for a specific zone, Vellux™ 100UI’s profile makes it exceptionally versatile for comprehensive facial rejuvenation. Its primary indication is for deep dermal and supraperiosteal injection to restore volume in the mid-face, such as the malar (cheek) and submalar regions. By building a strong foundation in the cheeks, it can create a non-surgical mid-face lift, indirectly improving the appearance of nasolabial folds and marionette lines by lifting the overlying tissue. It is also the filler of choice for augmenting the chin and pre-jawline, providing definition and contour that appears entirely natural due to the depth of placement. Advanced practitioners often use it in combination with more fluid fillers—a technique known as layering. For instance, Vellux™ 100UI can be placed deep for structural support, while a softer, smaller-particle HA filler is layered above it to smooth the superficial dermis. This approach allows for a truly customized, three-dimensional rejuvenation that addresses multiple signs of aging simultaneously.
Economic and Practical Value for Patients
Beyond the clinical benefits, the use of Vellux™ 100UI presents a compelling economic argument. The extended duration of effect, often lasting between 12 to 18 months, means patients require fewer syringes and fewer appointments over a multi-year period compared to fillers that last 6-9 months. When calculating the cost per month of aesthetic correction, Vellux™ 100UI frequently proves to be more cost-effective. For example, if a syringe of a standard filler costing $700 lasts 8 months, the monthly cost is $87.50. A syringe of Vellux™ 100UI, which may cost $900 but last for 16 months, brings the monthly cost down to $56.25, representing a significant long-term saving. This longevity also reduces the cumulative risk of potential complications associated with frequent needle insertions. From a practical standpoint, the product’s consistency allows for smooth extrusion through fine-gauge needles (typically 25G or 27G), making the injection process more controlled for the practitioner and less traumatic for the patient’s tissues.
The Role in Modern Aesthetic Treatment Protocols
In the evolving landscape of aesthetic medicine, Vellux™ 100UI has cemented its role as a foundational tool. It aligns perfectly with the modern shift towards a volumetric approach to facial aging, which prioritizes restoring lost volume over simply stretching skin. This approach yields more natural, refreshed outcomes rather than an over-filled or “worked-on” look. It is increasingly being integrated into combination therapies. For instance, it can be used alongside energy-based devices like microfocused ultrasound (Ultherapy) or radiofrequency (Morpheus8); the filler provides immediate volume correction, while the device stimulates long-term collagen and elastin production in the surrounding tissue, creating a synergistic effect. Its predictable behavior and safety profile also make it an excellent choice for practitioners who are refining their skills in advanced injection techniques, providing a reliable medium to achieve significant structural changes.